When Regulation Shapes Access: Why the ISLET Act Matters for Type 1 Diabetes
February 26, 2026
Across the diabetes policy landscape, innovation is moving fast but regulation often determines who actually benefits.
In the United States, the Increase Support for Life saving Endocrine Transplantation ISLET Act has emerged as an important policy proposal that could reshape access to islet transplantation for people living with type 1 diabetes. While highly technical on the surface, the debate surrounding the Act speaks to a broader global question: how can regulatory frameworks keep pace with life changing medical advances?
Understanding the policy shift
Islet transplantation involves infusing insulin producing cells from a donor pancreas into a person with type 1 diabetes, with the goal of restoring endogenous insulin production and reducing the burden of severe hypoglycaemia. In many countries, cadaveric islets are regulated within organ transplantation systems. In the United States, however, they have historically been regulated as biologic drugs, a distinction that has significant practical consequences.
The ISLET Act proposes to reclassify human cadaveric islets as organs for transplantation purposes. If enacted, this would align oversight more closely with the established transplant framework and potentially remove longstanding barriers that have limited the availability of islet transplantation programs in the United States.
Why this matters for people living with diabetes
For individuals with type 1 diabetes, particularly those experiencing recurrent severe hypoglycaemia, islet transplantation can offer meaningful clinical and quality of life benefits. Yet access has remained uneven and limited.
Supporters of the ISLET Act argue that the current regulatory pathway is outdated and has slowed clinical adoption. They believe reform could:
- Expand patient access to islet transplantation
- Enable more transplant centers to develop programs
- Encourage continued innovation in cell based therapies
- Better align United States practice with international approaches
At the same time, important considerations remain.
The policy questions that still need attention
As with many emerging health technologies, regulatory reform must balance access, safety, and sustainability.
Key issues that policymakers and the diabetes community continue to examine include:
- Ensuring robust safety and quality oversight
- Addressing the limited supply of donor islets
- Managing the ongoing need for immunosuppression
- Considering long term cost and reimbursement pathways
- Evaluating how islet transplantation fits within the broader diabetes care continuum
Importantly, the ISLET Act does not on its own solve the structural challenges of type 1 diabetes care. But it does highlight how regulatory design can either enable or constrain therapeutic progress.
A broader lesson for global diabetes policy
For parliamentarians and health leaders worldwide, the conversation around the ISLET Act offers a valuable case study.
As advanced therapies, including stem cell derived islets and other cell based approaches, move closer to clinical reality, countries will increasingly face similar questions:
- How should novel cell therapies be classified?
- What regulatory pathways best protect patients while enabling access?
- How can innovation be aligned with equity and affordability?
These are not purely technical decisions. They are fundamentally policy and governance choices that will shape the future of diabetes care.
Looking ahead
The ISLET Act remains under consideration in the United States. Regardless of its legislative outcome, the debate it has sparked is already instructive for the global diabetes community. For networks such as PDGN, the moment calls for continued parliamentary engagement, evidence informed dialogue, and careful attention to how regulatory frameworks can support both innovation and equitable access. Because in diabetes policy, as in many areas of health, how we regulate often determines who benefits.